EN BREF ...
"Prescription digital therapeutics (PDTx) is an emerging category of evidence-based treatment gaining traction as demand for remote solutions to treat mental health needs has accelerated in the COVID-19 era. Unlike wellness, telepsych or disease management apps, PDTx products pursue clearance through regulatory bodies in order to support their claims, akin to medical devices. In this whitepaper, Marwood explores how the defining features of PDTx in the larger digital health space impact market access considerations from a payor and provider perspective. Marwood also provides strategic guidance regarding market access pathways that could lead to widespread coverage and adoption of PDTx products, such as the Category I Common Procedural Terminology (CPT) code." En bref issu de l"étude.
Rédacteur(s) de la fiche : Beesens TEAM
Introductio
1 - In tincidunt nunc ac velit tristique
- Pellentesque congue, magna elementum suscipit vestibulum
- Aenean eleifend sodales ipsum vitae consequat
- Quisque est leo tempus vel purus eu, placerat tincidunt nisl
2 - Sed lobortis elit vitae mollis consectetur
- In tincidunt nunc ac velit tristique
- Donec accumsan elit ac ornare eleifend
- Sed pellentesque suscipit quam ut finibus
- Fusce imperdiet neque sit amet ipsum ullamcorper scelerisque
3 - Lorem ipsum dolor sit amet
- Pellentesque congue, magna elementum suscipit vestibulum
- Aenean eleifend sodales ipsum vitae consequat
- Quisque est leo tempus vel purus eu, placerat tincidunt nisl
Conclusio
Pour accéder à ce contenu,
créez votre compte
gratuitement
Accéder à :
- L'ensemble de la veille e-santé sélectionnée
par la communauté Beesens, - Des documents de références de la e-santé,
- Et bien plus encore...
Déjà inscrit ? Identifiez-vous